Journal Home > Volume 1 , Issue 2
Brain Science Advances 2015, 1(2): 75-85 https://doi.org/10.18679/CN11-6030_R.2015.009
Research Article | Open Access | Issue | Published: 01 December 2015

Differentiated cells derived from fetal neural stem cells improve motor deficits in a rat model of Parkinson’s disease

Show Author's Information Wei Wang,  Hao Song,  Aifang Shen,  Chao Chen,  Yanming Liu,  Yabing Dong,  Fabin Han( )
Centre for Stem Cells and Regenerative Medicine Liaocheng People’s Hospital/The Affiliated Liaocheng Hospital, Taishan Medical University, Liaocheng 252000, China
Keywords:
Parkinson’s disease, transplantation, differentiation, fetal neural stem cells, dopamine neuron
Cite this article:
Wang W, Song H, Shen A, et al. Differentiated cells derived from fetal neural stem cells improve motor deficits in a rat model of Parkinson’s disease. Brain Science Advances, 2015, 1(2): 75-85. https://doi.org/10.18679/CN11-6030_R.2015.009
Download citation
EndNote(RIS)
BibTeX

369

Views

7

Downloads

Citations

5

Crossref

N/A

WoS

N/A

Scopus

N/A

CSCD

Abstract Full text About this article
Objective:

Parkinson’s disease (PD), which is one of the most common neurodegenerative disorders, is characterized by the loss of dopamine (DA) neurons in the substantia nigra in the midbrain. Experimental and clinical studies have shown that fetal neural stem cells (NSCs) have therapeutic effects in neurological disorders. The aim of this study was to examine whether cells that were differentiated from NSCs had therapeutic effects in a rat model of PD.

Methods:

NSCs were isolated from 14-week-old embryos and induced to differentiate into neurons, DA neurons, and glial cells, and these cells were characterized by their expression of the following markers: βⅢ-tubulin and microtubule-associated protein 2 (neurons), tyrosine hydroxylase (DA neurons), and glial fibrillary acidic protein (glial cells). After a 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD was generated, the differentiated cells were transplanted into the striata of the 6-OHDA-lesioned PD rats.

Results:

The motor behaviors of the PD rats were assessed by the number of apomorphine-induced rotation turns. The results showed that the NSCs differentiated in vitro into neurons and DA neurons with high efficiencies. After transplantation into the striata of the PD rats, the differentiated cells significantly improved the motor deficits of the transplanted PD rats compared to those of the control nontransplanted PD rats by decreasing the apomorphine-induced turn cycles as early as 4 weeks after transplantation. Immunofluorescence analyses showed that the differentiated DA neurons survived more than 16 weeks.

Conclusions:

Our results showed that cells that were differentiated from NSCs had therapeutic effects in a rat PD model, which suggests that differentiated cells may be an effective treatment for patients with PD.


menu
Abstract
Full text
Outline
About this article

Differentiated cells derived from fetal neural stem cells improve motor deficits in a rat model of Parkinson’s disease

Show Author's information Wei Wang, Hao Song, Aifang Shen, Chao Chen, Yanming Liu, Yabing Dong, Fabin Han( )
Centre for Stem Cells and Regenerative Medicine Liaocheng People’s Hospital/The Affiliated Liaocheng Hospital, Taishan Medical University, Liaocheng 252000, China

Abstract

Objective:

Parkinson’s disease (PD), which is one of the most common neurodegenerative disorders, is characterized by the loss of dopamine (DA) neurons in the substantia nigra in the midbrain. Experimental and clinical studies have shown that fetal neural stem cells (NSCs) have therapeutic effects in neurological disorders. The aim of this study was to examine whether cells that were differentiated from NSCs had therapeutic effects in a rat model of PD.

Methods:

NSCs were isolated from 14-week-old embryos and induced to differentiate into neurons, DA neurons, and glial cells, and these cells were characterized by their expression of the following markers: βⅢ-tubulin and microtubule-associated protein 2 (neurons), tyrosine hydroxylase (DA neurons), and glial fibrillary acidic protein (glial cells). After a 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD was generated, the differentiated cells were transplanted into the striata of the 6-OHDA-lesioned PD rats.

Results:

The motor behaviors of the PD rats were assessed by the number of apomorphine-induced rotation turns. The results showed that the NSCs differentiated in vitro into neurons and DA neurons with high efficiencies. After transplantation into the striata of the PD rats, the differentiated cells significantly improved the motor deficits of the transplanted PD rats compared to those of the control nontransplanted PD rats by decreasing the apomorphine-induced turn cycles as early as 4 weeks after transplantation. Immunofluorescence analyses showed that the differentiated DA neurons survived more than 16 weeks.

Conclusions:

Our results showed that cells that were differentiated from NSCs had therapeutic effects in a rat PD model, which suggests that differentiated cells may be an effective treatment for patients with PD.

Keywords: Parkinson’s disease, transplantation, differentiation, fetal neural stem cells, dopamine neuron

References(48)

[1]
Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease. J Neurosci 2001, 21(17): 6853-6861.
DOI Google Scholar
[2]
de Rijk MC, Launer LJ, Berger K, Breteler MMB, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurology 2000, 54(11 Suppl 5): S21-S23.
Google Scholar
[3]
Han FB, Wang W, Chen BX, Chen C, Li S, Lu XJ, Duan J, Zhang Y, Zhang YA, Guo WN, Li GY. Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson’s disease. Cytotherapy 2015, 17(5): 665-679.
DOI Google Scholar
[4]
Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009, 169(8): 919-926.
DOI Google Scholar
[5]
Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and mitophagy in Parkinson’s: From familial to sporadic disease. Trends Biochem Sci 2015, 40(4): 200-210.
DOI Google Scholar
[6]
Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: Molecules to medicine. J Clin Invest 2006, 116(7): 1744-1754.
DOI Google Scholar
[7]
Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P. Risk of dementia in Parkinson’s disease: A community-based, prospective study. Neurology 2001, 56(6): 730-736.
DOI Google Scholar
[8]
Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2009, 373(9680): 2055-2066.
DOI Google Scholar
[9]
Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease: Problems with the current model. Ann Neurol 2000, 47(4 Suppl 1): S22-S32.
Google Scholar
[10]
Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010, 67(6): 715-725.
DOI Google Scholar
[11]
Bergman H, Deuschl G. Pathophysiology of Parkinson’s disease: From clinical neurology to basic neuroscience and back. Mov Disord 2002, 17(Suppl 3): S28-S40.
DOI Google Scholar
[12]
Lee HM, Koh SB. Many faces of Parkinson’s disease: Non-motor symptoms of Parkinson’s disease. J Mov Disord 2015, 8(2): 92-97.
DOI Google Scholar
[13]
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004, 351(24): 2498-2508.
Google Scholar
[14]
Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol 2006, 5(3): 235-245.
DOI Google Scholar
[15]
Meyer AK, Maisel M, Hermann A, Stirl K, Storch A. Restorative approaches in Parkinson’s disease: Which cell type wins the race? J Neurol Sci 2010, 289(1-2): 93-103.
DOI Google Scholar
[16]
Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang LC, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 2011, 480(7378): 547-551.
DOI Google Scholar
[17]
Han FB. The applications of the induced pluripotent stem cells in studying the neurodegenerative diseases. Chin J Cell Biol 2012, 34(5): 403-414. (in Chinese)
Google Scholar
[18]
Fricker RA, Carpenter MK, Winkler C, Greco C, Gates MA, Björklund A. Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J Neurosci 1999, 19(14): 5990-6005.
DOI Google Scholar
[19]
Nishino H, Hida H, Takei N, Kumazaki M, Nakajima K, Baba H. Mesencephalic neural stem(progenitor) cells develop to dopaminergic neurons more strongly in dopamine-depleted striatum than in intact striatum. Exp Neurol 2000, 164(1): 209-214.
DOI Google Scholar
[20]
Andersson E, Tryggvason U, Deng QL, Friling S, Alekseenko Z, Robert B, Perlmann T, Ericson J. Identification of intrinsic determinants of midbrain dopamine neurons. Cell 2006, 124(2): 393-405.
DOI Google Scholar
[21]
Burbach JPH, Smidt MP. Molecular programming of stem cells into mesodiencephalic dopaminergic neurons. Trends Neurosci 2006, 29(11): 601-603.
DOI Google Scholar
[22]
Kim HJ, McMillan E, Han FB, Svendsen CN. Regionally specified human neural progenitor cells derived from the mesencephalon and forebrain undergo increased neurogenesis following overexpression of ASCL1. Stem Cells 2009, 27(2): 390-398.
DOI Google Scholar
[23]
Gonzalez C, Bonilla S, Flores AI, Cano E, Liste I. An update on human stem cell-based therapy in Parkinson’s disease. Curr Stem Cell Res Ther, in press, .
DOI Google Scholar
[24]
Papanikolaou T, Lennington JB, Betz A, Figueiredo C, Salamone JD, Conover JC. In vitro generation of dopaminergic neurons from adult subventricular zone neural progenitor cells. Stem Cells Dev 2008, 17(1): 157-172.
DOI Google Scholar
[25]
Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi JX, Lone T, Zhang YB, Snyder JA, Wells TH, Ramig LO, Thompson L, Mazziotta JC, Huang SC, Grafton ST, Brooks D, Sawle G, Schroter G, Ansari AA. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease. N Engl J Med 1992, 327(22): 1549-1555.
DOI Google Scholar
[26]
Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, Hauser RA, Smith DA, Nauert GM, Perl DP, Olanow CW. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 1995, 332(17): 1118-1124.
DOI Google Scholar
[27]
Lindvall O, Sawle G, Widner H, Rothwell JC, Björklund A, Brooks D, Brundin P, Frackowiak R, Marsden CD, Odin P, Rehncrona S. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson’s disease. Ann Neurol 1994, 35(2): 172-180.
DOI Google Scholar
[28]
Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001, 344(10): 710-719.
DOI Google Scholar
[29]
Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD, Björklund A. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science 1990, 247(4942): 574-577.
DOI Google Scholar
[30]
Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol 2001, 60(8): 741-752.
DOI Google Scholar
[31]
Lindvall O, Björklund A. Cell therapy in Parkinson’s disease. Neuro Rx 2004, 1(4): 382-393.
DOI Google Scholar
[32]
Barker RA, Barrett J, Mason SL, Björklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson’s disease. Lancet Neurol 2013, 12(1): 84-91.
DOI Google Scholar
[33]
Svendsen CN, Caldwell MA, Shen J, ter Borg MG, Rosser AE, Tyers P, Karmiol S, Dunnett SB. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson’s disease. Exp Neurol 1997, 148(1): 135-146.
DOI Google Scholar
[34]
Kallur T, Darsalia V, Lindvall O, Kokaia Z. Human fetal cortical and striatal neural stem cells generate region-specific neurons in vitro and differentiate extensively to neurons after intrastriatal transplantation in neonatal rats. J Neurosci Res 2006, 84(8): 1630-1644.
DOI Google Scholar
[35]
Yan YP, Yang DL, Zarnowska ED, Du ZW, Werbel B, Valliere C, Pearce RA, Thomson JA, Zhang SC. Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. Stem Cells 2005, 23(6): 781-790.
DOI Google Scholar
[36]
Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, Moore M, Osborn T, Cooper O, Spealman R, Hallett P, Isacson O. Improved cell therapy protocols for Parkinson’s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 2013, 31(8): 1548-1562.
DOI Google Scholar
[37]
Lu P, Wang YZ, Graham L, McHale K, Gao MY, Wu D, Brock J, Blesch A, Rosenzweig ES, Havton LA, Zheng BH, Conner JM, Marsala M, Tuszynski MH. Long-distance growth and connectivity of neural stem cells after severe spinal cord injury. Cell 2012, 150(6): 1264-1273.
DOI Google Scholar
[38]
Eriksson PS, Perfilieva E, Björk-Eriksson T, Alborn AM, Nordborg C, Peterson DA, Gage FH. Neurogenesis in the adult human hippocampus. Nat Med 1998, 4(11): 1313-1317.
DOI Google Scholar
[39]
Doetsch F, Caillé I, Lim DA, García-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999, 97(6): 703-716.
DOI Google Scholar
[40]
Taupin P, Gage FH. Adult neurogenesis and neural stem cells of the central nervous system in mammals. J Neurosci Res 2002, 69(6): 745-749.
DOI Google Scholar
[41]
Brundin P, Nilsson OG, Strecker RE, Lindvall O, Åstedt B, Björklund A. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson’s disease. Exp Brain Res 1986, 65(1): 235-240.
DOI Google Scholar
[42]
Studer L, Tabar V, McKay RD. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci 1998, 1(4): 290-295.
DOI Google Scholar
[43]
Monni E, Cusulin C, Cavallaro M, Lindvall O, Kokaia Z. Human fetal striatum-derived neural stem (NS) cells differentiate to mature neurons in vitro and in vivo. Curr Stem Cell Res Ther 2014, 9(4): 338-346.
DOI Google Scholar
[44]
Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. NatBiotechnol 2009, 27(3): 275-280.
DOI Google Scholar
[45]
Yang DL, Zhang ZJ, Oldenburg M, Ayala M, Zhang SC. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 2008, 26(1): 55-63.
DOI Google Scholar
[46]
Roy NS, Cleren C, Singh SK, Yang LC, Beal MF, Goldman SA. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 2006, 12(11): 1259-1268.
DOI Google Scholar
[47]
Björklund A, Lindvall O. Cell replacement therapies for central nervous system disorders. Nat Neurosci 2000, 3(6): 537-544.
DOI Google Scholar
[48]
Kang XJ, Xu HD, Teng SS, Zhang XY, Deng ZJ, Zhou L, Zuo PL, Liu B, Wu QH, Wang L, Hu MQ, Dou HQ, Liu W, Zhu FP, Li Q, Guo S, Gu JL, Lei Q, Lv J, Mu Y, Jin M, Wang SR, Jiang W, Liu K, Wang CH, Li WL, Zhang K, Zhou Z. Dopamine release from transplanted neural stem cells in Parkinsonian rat striatum in vivo. Proc Natl Acad Sci USA 2014, 111(44): 15804-15809.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 09 October 2015
Revised: 27 November 2015
Accepted: 30 November 2015
Published: 01 December 2015
Issue date: December 2015

Copyright

© The authors 2015.

Acknowledgements

We would like to thank all the participants in the study. Funding was supported by the National Natural Science Foundation of China (NSFC, No. 81271251).

Rights and permissions

This article is published with open access at www.TNCjournal.com

Return